Myeloproliferative neoplasms - a global view

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Clinical Hematology, University Hospital of Brest, Brest, France.
³ Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
⁴ Department of Hematology, Linköping University Hospital, Linköping, Sweden.
⁵ Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.
⁶ MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
⁷ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Ayalew Tefferi et al. Br J Haematol. 2022 Sep.

. 2022 Sep;198(6):953-964.

doi: 10.1111/bjh.18213. Epub 2022 Apr 28.

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Clinical Hematology, University Hospital of Brest, Brest, France.
³ Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
⁴ Department of Hematology, Linköping University Hospital, Linköping, Sweden.
⁵ Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.
⁶ MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
⁷ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

No abstract available

References

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-5.
1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
1. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90.